Diagnostic ureteroscopy for upper tract urothelial carcinoma: friend or foe?
Diagnostic biopsy
diagnosis
radical nephroureterectomy
upper tract urothelial carcinoma
ureteroscopy
Journal
Arab journal of urology
ISSN: 2090-598X
Titre abrégé: Arab J Urol
Pays: United States
ID NLM: 101562480
Informations de publication
Date de publication:
16 Feb 2021
16 Feb 2021
Historique:
entrez:
25
3
2021
pubmed:
26
3
2021
medline:
26
3
2021
Statut:
epublish
Résumé
The European Association of Urology guidelines recommend offering kidney-sparing surgery (KSS) as a primary treatment option to patients with low-risk tumours. Cystoscopy, urinary cytology, and computed tomography urography (CTU) do not always allow correct disease staging and grading, and sometimes there is even a lack of certainty regarding the diagnosis of UTUC. Diagnostic ureteroscopy (d-URS) may therefore be of crucial importance within the diagnostic framework and fundamental in establishing the appropriate therapeutic approach. A systematic review of the literature was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Risk of bias was assessed using Risk of Bias in Non-randomized Studies of interventions (ROBINS-I). Overall, from 3791 identified records, 186 full-text articles were assessed for eligibility. Finally, after a quantitative review of the selected literature, with the full agreement of all authors, 62 studies were considered relevant for this review. CTU has a sensitivity and specificity for UTUC of 92% and 95% respectively, but is not able to detect small or flat lesions with adequate accuracy. The sensitivity of voided urinary cytology for UTUC is around 67-76% and ranges from 43% to 78% for selective ureteric urine collection. As no technique offers a diagnosis of certainty, d-URS can allow an increase in diagnostic accuracy. In the present review the pros and cons of d-URS were analysed. This technique may provide additional information in the selection of patients suitable for neoadjuvant chemotherapy or KSS, distinguishing between normal tissue and low- and high-grade UTUC thanks to the emerging technologies. Information obtainable from d-URS and ureteroscopic-guided biopsy can prove extremely valuable when the diagnosis of UTUC is doubtful or KSS is being considered. Notwithstanding concerns remain regarding the potential risk of bladder recurrence, cancer dissemination, and/or delay in radical treatment.
Identifiants
pubmed: 33763248
doi: 10.1080/2090598X.2021.1883810
pii: 1883810
pmc: PMC7954478
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
46-58Informations de copyright
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the authors.
Références
World J Urol. 2017 Mar;35(3):355-365
pubmed: 27233780
BJU Int. 2017 Sep;120(3):313-319
pubmed: 28621055
J Urol. 2013 Feb;189(2):580-4
pubmed: 22982421
Eur Urol Focus. 2018 Dec;4(6):954-959
pubmed: 28753800
Eur Urol. 2014 Jan;65(1):210-7
pubmed: 22579047
Urology. 2018 Nov;121:66-73
pubmed: 29964129
J Urol. 2010 Jul;184(1):69-73
pubmed: 20478585
J Endourol. 2012 Apr;26(4):398-402
pubmed: 22192113
World J Surg Oncol. 2018 Jul 9;16(1):135
pubmed: 29986730
J Endourol. 2017 Mar;31(3):259-265
pubmed: 27785917
BMC Urol. 2015 Jul 25;15:74
pubmed: 26209444
BJU Int. 2010 Mar;105(6):812-7
pubmed: 19732052
Urology. 2018 Jul;117:89-94
pubmed: 29630955
PLoS One. 2015 Nov 10;10(11):e0139976
pubmed: 26556239
J Urol. 1999 Mar;161(3):783-5
pubmed: 10022684
J Urol. 2018 Jan;199(1):66-73
pubmed: 28818526
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Eur Urol. 2016 Dec;70(6):1052-1068
pubmed: 27477528
J Endourol. 2014 Aug;28(8):922-5
pubmed: 24742232
BJU Int. 2017 Feb;119(2):289-297
pubmed: 27611622
World J Urol. 2014 Aug;32(4):1033-40
pubmed: 24135917
BJU Int. 2019 Feb 23;:
pubmed: 30801918
World J Urol. 2013 Feb;31(1):69-76
pubmed: 23070533
J Urol. 2000 Jan;163(1):52-5
pubmed: 10604312
World J Urol. 2019 Sep;37(9):1899-1905
pubmed: 30560298
J Endourol. 2017 May;31(5):438-445
pubmed: 28001097
Clin Cancer Res. 2019 Feb 1;25(3):967-976
pubmed: 30352907
J Endourol. 2015 Dec;29(12):1418-23
pubmed: 26413927
J Endourol. 2013 Dec;27(12):1450-4
pubmed: 24251426
Clin Genitourin Cancer. 2016 Feb;14(1):e37-41
pubmed: 26459040
Urology. 1997 Jul;50(1):117-9
pubmed: 9218030
Pathol Oncol Res. 2018 Jan;24(1):89-94
pubmed: 28374346
Cancer. 2010 Jun 15;116(12):2967-73
pubmed: 20564402
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
World J Urol. 2017 May;35(5):819-826
pubmed: 27604373
J Endourol. 1994 Apr;8(2):111-3
pubmed: 8061666
J Urol. 2021 Feb;205(2):392-399
pubmed: 32935620
J Urol. 2016 Dec;196(6):1749-1755
pubmed: 27475968
J Endourol. 2011 Jan;25(1):19-23
pubmed: 21247287
Cancer. 2014 Jun 15;120(12):1794-9
pubmed: 24633966
Eur Urol. 2018 Jan;73(1):111-122
pubmed: 28867446
J Urol. 2010 Sep;184(3):883-7
pubmed: 20643446
World J Urol. 2017 Apr;35(4):675-681
pubmed: 27492012
Eur J Surg Oncol. 2020 Nov;46(11):1989-1997
pubmed: 32674841
World J Urol. 2020 May;38(5):1165-1175
pubmed: 31321509
Urology. 2005 Aug;66(2):283-7
pubmed: 16098357
Urol Oncol. 2012 May-Jun;30(3):266-72
pubmed: 20869888
J Urol. 1993 Jan;149(1):109-11
pubmed: 8417187
Eur Urol. 2011 Oct;60(4):703-10
pubmed: 21684068
Int J Mol Sci. 2019 Feb 13;20(4):
pubmed: 30781730
BJU Int. 2018 Feb;121(2):184-193
pubmed: 29032580
J Urol. 2010 Jun;183(6):2154-60
pubmed: 20399464
Urol Clin North Am. 2004 Feb;31(1):157-71
pubmed: 15040412
J Endourol. 2011 May;25(5):775-9
pubmed: 21388245
J Endourol. 2008 Jan;22(1):71-6
pubmed: 18315477
BJU Int. 2011 Sep;108(5):701-5
pubmed: 21320275
Curr Opin Urol. 2016 Jan;26(1):63-9
pubmed: 26555686
Eur Urol. 2006 Dec;50(6):1176-82
pubmed: 16846680
Int Braz J Urol. 2017 May-Jun;43(3):476-480
pubmed: 28338307
Scand J Urol. 2017 Apr;51(2):137-145
pubmed: 28385123